tenecteplase

Also known as t-plasminogen activator, tPA, Tissue-type plasminogen activator precursor, t- PA, TNK-TPA

Tenecteplase, sold under the brand name Metalyse among others, is an enzyme used as a thrombolytic drug.

Key facts

Drug.Verifiedfields: changed
Drug.verifiedrevid: 477861633
Drug.tradename: Metalyse
Drug.MedlinePlus: a625007
Drug.DailyMedID: Tenecteplase
Drug.routes_of_administration: Intravenous
Drug.class: Tissue plasminogen activator
Drug.ATC_prefix: B01
Drug.ATC_suffix: AD11
Drug.legal_US: Rx-only
Drug.legal_status: Rx-only
Drug.excretion: Liver
Drug.CAS_number: 191588-94-0
Drug.DrugBank: DB00031
Drug.ChemSpiderID: none
Drug.UNII: WGD229O42W
Drug.KEGG: D02837
Drug.IUPAC_name: Human tissue plasminogen activator

via Wikipedia infobox

Research

1,410 papers

Tenecteplase vs Alteplase for Patients With Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial.JAMA · 2024
Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy.The New England journal of medicine · 2024
Tenecteplase Thrombolysis for Acute Ischemic Stroke.Stroke · 2020
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.Lancet (London, England) · 2023
Evolving Thrombolytics: from Alteplase to Tenecteplase.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023

via PubMed

Wikidata facts

Show 2 more facts

chemical formula: C₂₅₆₁H₃₉₁₉N₇₄₇O₇₈₁S₄₀
defined daily dose: 40

Sources (6)

via Wikidata · CC0

~2 min read

Article

6 sections

Contents

Medical uses
Pharmacokinetics
Gallery
Research
References
Further reading

Tenecteplase, sold under the brand name Metalyse among others, is an enzyme used as a thrombolytic drug.

Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.